Article
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Lung cancer (Amsterdam, Netherlands) - 1 May 2015
Fukuhara Tatsuro, Maemondo Makoto, Inoue Akira, Kobayashi Kunihiko, Sugawara Shunichi, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Harada Masao, Yoshizawa Hirohisa, Kinoshita Ichiro, Fujita Yuka, Saijo Yasuo, Hagiwara Koichi, Morita Satoshi, Nukiwa Toshihiro
Abstract excerpt
INTRODUCTION: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations. The NEJ002 phase 3 clinical trial demonstrated the efficacy of EGFR-TKI; gefitinib was significantly superior in both progression-free survival (PFS) and objective response rate (ORR) than carboplatin plus paclitaxel....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.